Cite
HARVARD Citation
Strijbis, E. et al. (2022). The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Multiple sclerosis. pp. 1606-1619. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Strijbis, E. et al. (2022). The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. Multiple sclerosis. pp. 1606-1619. [Online].